NewExecutive Director, Market Access Allogene TherapeuticsExecutive Director, Market AccessSouth San Francisco, CARemote$280,000–$320,000 / yearGiven the unique complexities of CAR T therapy, this role will play a critical part in addressing site-of-care dynamics, center-of-excellence (COE) networks, single case agreements, and innovative payment models to enable broad access across both academic and community oncology settings. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Executive Director, Global Patient Safety Quality And Compliance - Pharmacovigilance Revolution Medicines, Inc.Executive Director, Global Patient Safety Quality And Compliance - PharmacovigilanceRedwood City, CA$265,000–$331,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Executive Director, GxP Quality and Compliance Revolution MedicinesExecutive Director, GxP Quality and ComplianceRedwood City, California$265,000–$331,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. 15+ years of progressive experience in GxP Quality and Compliance within the pharmaceutical, biotechnology, medical device, or related life sciences industry with extensive knowledge of FDA regulations, ICH Guidelines, EU GMP, and global GxP requirements.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Development Revolution Medicines, Inc.Executive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
NewTax Equity Originator - Executive Director Wells Fargo BankTax Equity Originator - Executive DirectorSan Francisco, California$215,000–$355,000 / yearLead cross-functional initiatives to develop new products or asset classes, enter new markets, or build new systems which create incremental revenue, increase profitability, demonstrate market leadership, capture internal efficiencies, and provide avenues for growth. They are accountable for execution of all applicable risk programs (Credit, Market, Financial Crimes, Operational, Regulatory Compliance), which includes effectively following and adhering to applicable Wells Fargo policies and procedures, appropriately fulfilling risk and compliance obligations, timely and effective escalation and remediation of issues, and making sound risk decisions.
Executive Director, Biologics Innovation & Strategy Exelixis Inc.Executive Director, Biologics Innovation & StrategyAlameda, CA$268,500–$380,500 / yearSuperlative Interaction and collaboration skills and communications across multiple departments and functions in both research and development parts of the organization as well as the ability to represent Exelixis with external collaboration colleagues to discuss and resolve project needs and issues in research and development of biotherapeutics. As a member of the Biotherapeutics team, the Executive Director of Biologics Innovation & Strategy plays a key role in leading the efforts for advancing the development of antibody drug conjugates (ADCs) and other biologics for oncology-based molecules at Exelixis.
NewExecutive Director, Scientific Publications (Oncology) Exelixis Inc.Executive Director, Scientific Publications (Oncology)Alameda, CA$273,000–$388,000 / yearResponsibilities include management of the Publications team, oversight of publication planning for each Exelixis development compound, coordination of publication planning and tactical execution with cross-functional collaborators, contribution to publication project execution as needed, management of publication vendors and responsibility for compliance aspects of the publication function. EDUCATION/EXPERIENCE/KNOWLEDGE & SKILLS: Education/Experience: Doctorate level degree (PharmD, MD, PhD) with a minimum of 15 years of related experience; or, Master's level degree in related discipline and a minimum of 16 years of related experience; or, Bachelor's level degree in related discipline and a minimum of 18 years of related experience; or, Equivalent combination of education and experience.
Executive Director, Innovation Banking Fifth Third BankExecutive Director, Innovation BankingSan Francisco, California$121,900–$262,100 / yearSuccessful candidates will demonstrate a higher degree of proficiency (typically from 8+ years of practical experience or advanced academic exposure) across the following areas: Client Advisory & Relationship Management – Ability to lead conversations, build trust, and deliver tailored solutions that deepen client relationships. . Provides support to the Capital Markets businesses by assessing whether securities products and capital markets services would be appropriate for a particular client and working with the Capital Markets teams to provide those products and services to clients. .
Executive Director, Digital Enablement VaxcyteExecutive Director, Digital EnablementSan Carlos, California$288,000–$335,000 / yearReports to: Chief Commercial Officer Location: US – Philadelphia/Remote Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Remote Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component. Own and maintain a commercial product roadmap that treats each digital capability — CRM, marketing technology, field enablement, analytics, AI tools — as a discrete product with a use case, a user, a success metric, and a release schedule.
Executive Director, Regulatory Affairs CMC AllakosExecutive Director, Regulatory Affairs CMCRedwood City, CaliforniaLeads the development of strategic CMC plans and tactical implementation for the creation and submission of Regulatory documents, e.g., INDs, BLAs, CTAs, MAAs, and other relevant regulatory filings. Exec Director Regulatory Affairs/CMC Allakos Inc. is a dynamic clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.
Executive Director Potrero GroupExecutive DirectorSan Francisco, CaliforniaThis role requires a strong communicator who can engage diverse audiences from scientific experts to community groups, and translate complex science into compelling narratives. The incoming Executive Director will lead a thriving organization known for its rigorous, unbiased scientific research and strong regional partnerships during an exciting period of growth.
Executive Director Atria Senior Living - Willow GlenExecutive DirectorSan Jose, CaliforniaThis individual recruits and trains team members and has direct supervisory responsibility for a high performing team of leaders in the disciplines of sales, care, hospitality, and resident engagement. Develop and implement successful strategies regarding labor, occupancy growth, revenue growth, expense control, and quality of services, and review and redirect activity, if necessary.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution MedicinesExecutive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, California$265,000–$331,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Mercy Brown Bag - Executive Director Transforming AgeMercy Brown Bag - Executive DirectorOakland, CaliforniaManages, leads, and develops staff to include Food Recovery Program Consultant and Assistant Director, who in turn oversees External and Internal Operations Managers, Development, Volunteer Manager, and all warehouse, and food distribution team members. Collaborates with team and key stakeholders and team and key stakeholders to formulate and effectively communicate the impact of MBBP, backed by key data and visual tools.
NewDEPUTY EXECUTIVE DIRECTOR People With Disabilities FoundationDEPUTY EXECUTIVE DIRECTORSan Francisco, CA$78,000–$82,000 / year3. Knowledge of GAAP and bookkeeping, IT skills, employment laws and HR skills, working with and resolving vendor disputes, and nonprofit tax return filing (we have a CPA). 2. General knowledge of disability civil rights and Social Security/SSI disability necessary to administratively oversee PWDF’s programs or equivalent experience.
NewExecutive Director, Global Patient Safety Quality and Compliance - Pharmacovigilance Revolution MedicinesExecutive Director, Global Patient Safety Quality and Compliance - PharmacovigilanceRedwood City, California$252,000–$315,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Executive Director, Computational Systems Biology Revolution MedicinesExecutive Director, Computational Systems BiologyRedwood City, California$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.